WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 4'2401 Infant (under 12 months) mortality rate: 132
GDP / capita (US$): 5'0261 Child (under 5 years) mortality rate: 152

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 105  105  104  104  103  98  95  93 
Births
Surviving infants
Pop. less than 5 years 14  14  14  14  14  13  13  13 
Pop. less than 15 years 39  39  39  39  39  38  38  39 
Female 15-49 years 25  25  25  25  25  23  22  21 

Number of reported case

(Click for retrospective incidence data for Tonga)
Diphtheria
Japanese encephalitis
Measles 65  2'336 
Mumps
Pertussis
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Tonga)
Vaccine year result method % card seen                                                
BCG 2002  87       95  100  99  99  99  99  99  99 
DTP1          95  100  99  99  100  99 
DTP3 2002  96       95  100  99  99  100  95  94  40 
HepB_BD          95  100  99  99  99  100 
HepB3 2002  94       95  100  99  99  98  97  94 
Hib3          95  100  99  99  99 
JapEnc         
MCV 2002  84       95  99  99  99  100  86 
MCV2          95  99  98  98  98 
PCV1         
PCV3         
Pol3 2002  96       95  100  99  99  100  95  93  20 
Rota1         
Rota_last         
Rubella1          95  99  99  99  100 
TT2plus          95  98  98  98  99  94  65 
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Tonga)
BCG 95  99  99  99  99  99  99  99 
DTP1 95  99  99  99  99  99  97  65 
DTP3 95  99  99  99  99  95  94  40 
HepB3 95  99  99  99  98  97  94 
Hib3 95  99  99  99  99 
MCV 95  99  99  99  99  95  86 
PCV3
Pol3 95  99  99  99  99  95  93  20 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaP 18 months; 6 years; Yes
DTaPHibHep 6, 10, 14 weeks; Yes
HepB birth; Yes and health care workers
MR 12, 18 months; Yes
OPV 6, 10, 14 weeks; Yes
Td Yes students and pregnant women

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2012-2014  2009-2013  2009 - 2012  2009-2012  2009 - 2012  2005 - 2008  2005 - 2007 
Nº of districts with microplans that include activities to raise immunization coverage number

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number    
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  100  100  100     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND No  Yes  Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 2'500  100  90  95  80  56  75 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.